Brief: Nicox Completes End-of-Phase 2 Meeting With the U.S. FDA

Nicox SA

05/03/2020 06:39

March 5 (Reuters) - NICOX SA  NCOX.PA :
    * NICOX’S POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FDA
SETS
STAGE FOR NCX 470 PHASE 3 PROGRAM IN GLAUCOMA
    * MONT BLANC TRIAL, FIRST PHASE 3 CLINICAL TRIAL OF NCX 470,
IS
EXPECTED TO START BY END OF Q2 2020
    * WE ARE ON TRACK TO INITIATE FIRST PIVOTAL CLINICAL TRIAL
BY END
OF Q2 2020
    * TOP-LINE RESULTS EXPECTED IN Q3 2021

Source text for Eikon:  ID:nGNE3T35jY 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))